This diabetic medication through its amazing properties can help our body to be enhanced in sensitivity towards the insulin produced in body as the diabetic disorder infects this property and can impel our body not to respond the absorption and utilization phenomenon https://unica-web.com/archive/2018/TATIANA-ALAHVERDZHIEVA-candidate-UNICA2018.html order viagra of insulin to develop type-2 diabetes. Prostate is the largest subsidiary gland of a man, which always guards the purchase cheap viagra https://unica-web.com/watch/2017/taxi.html bladder like a solider. Your dentist can help you with the best possible medicine and viagra ordination https://unica-web.com/ENGLISH/2016/GA2016-minutes-2.html would guide you a proper path which would lead to best results curing this erectile dysfunction. Both partners in an affiliation levitra pharmacy https://www.unica-web.com/graphics/1981-images/unica50years006.pdf know how to market and this is the ONLY place where you are going to the proper training you need! InLife Training In this InLife business review, I am going to lead this market.
German pharmaceutical company Cheplapharm Arzneimittel has signed an agreement to purchase global commercial rights for Losec (omeprazole) from AstraZeneca for $243m.
Under the agreement, Cheplapharm will also purchase brands associated with Losec.
AstraZeneca has agreed to sell the global commercial rights to Losec, excluding China, Japan, the US and Mexico.
The sale includes medicines containing omeprazole marketed by the company or its collaborators under the brands Acimax, Antra, Mepral, Mopral, Omepral and Zoltum.
Cheplapharm will make the initial payment of $243m to AstraZeneca upon completion of the agreement. AstraZeneca will also receive $33m in contingent payments in 2021 and 2022.
AstraZeneca biopharmaceuticals executive vice-president Ruud Dobber said: “This agreement forms part of our strategy of reducing the portfolio of mature medicines to enable reinvestment in our main therapy areas, accelerating the number of innovative new medicines for patients with high unmet medical need.
[huge_it_slider id=”15″]“We already have an excellent relationship with Cheplapharm and their strong European presence and global distribution network will help ensure continued patient access to Losec.”
Under the agreement, AstraZeneca will continue to manufacture and supply Losec and its associated medicines, commercialising them in regions where it still retains the rights.
AstraZeneca said: “The commercial rights to Losec and other omeprazole medicines in the US, Japan and Mexico, as well as the commercial rights to the over-the-counter version in France, Finland, Ireland, New Zealand and the Netherlands were previously divested.”
Developed by AstraZeneca, Losec is a proton pump inhibitor that helps to minimise the amount of acid produced by the stomach in patients with gastrointestinal reflux conditions and ulcers.
Last July, AstraZeneca signed an agreement to sell the European commercial rights for its Atacand (candesartan cilexetil) drug to Cheplapharm Arzneimittel for $200m.